SCHEMBL966822

SCHEMBL966822

O=C(CN1CCn2c(nc3cc(-c4cccnn4)ccc32)C1)N1CCN(C2CCC2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.42
MAPT P10636 10/20 0.42
KDM4E B2RXH2 10/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
GAA P10253 2/20 0.42
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
HPGD P15428 3/20 0.41
MEN1 O00255 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 1/20 0.41
POLB P06746 1/20 0.40
RECQL P46063 1/20 0.40
CASP1 P29466 2/20 0.40
HSD17B10 Q99714 2/20 0.40
CASP7 P55210 1/20 0.40
MCL1 Q07820 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL418895 0.81 MAPT (0.41) ALDH1A1MAPTKDM4ESMN1; SMN2GAA
SCHEMBL969808 0.81 TSHR (0.50) ALDH1A1MAPTKDM4ESMN1; SMN2GAA
SCHEMBL1017101 0.79 ALDH1A1 (0.39) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL970389 0.76 SIGMAR1 (0.41) ALDH1A1MAPTKDM4ESMN1; SMN2GAA
SCHEMBL13985934 0.76 PARP1 (0.34) ALDH1A1KDM4ESMN1; SMN2KMT2ASIGMAR1
SCHEMBL968574 0.75 SIGMAR1 (0.47) ALDH1A1KDM4ESMN1; SMN2SIGMAR1PARP1
SCHEMBL1017220 0.72 PARP1 (0.38) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL967063 0.72 SIGMAR1 (0.41) ALDH1A1MAPTKDM4EHPGDMEN1
SCHEMBL968150 0.72 SIGMAR1 (0.47) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL1016681 0.71 ALDH1A1 (0.38) ALDH1A1MAPTKDM4ESMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 ALDH1A1 812/4885MAPT 3870/4885KDM4E 3037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.